No one can prove the future, although we bet on the outcomes. Joe was dealt a lousy hand just as he was set to launch Excellagen in VA hospitals and open his vision of health clinics. And now, with Malaysia in an iron fist lockdown, Excellagen probably was dealt another temporary set back, although I’m not sure about that. Yet in the US, those VA hospitals and centers are reopening to full care. So the timeline for proving Excellagen worth as an investment is starting now into the 10 k in October and the subsequent Q. The Q in June shows the prior period so nothing happened then. But if nothing noteworthy is in the subsequent two filings I’d be surprised. And I’d stop believing in Excellagen. The next six months are vital in establishing worth in any investment in Excellagen. Jmho
——
Terry Thompson Gnbt CC May 2021
“I have been informed, with a high degree of confidence, that a current investor, is in the final stages of a financial commitment toward our restart. This investment will be used to re-establish our sales program for Excellagen on several fronts. Upon closing of this financing, we will complete our current bulk inventory. This will produce over 20,000 syringes which has a revenue potential of tens of millions of dollars. As the VA hospitals begin to re-open, we are positioned with a best-in-class product to methodically offer our wound healing product with our new international partners & building our brand starting with the VA hospital network.””
(4)
(0)
Generex Biotechnology Corp. (GNBTQ) Stock Research Links